 |
|
|
|
|
|
|
|
 |
Results for 'Alzheimer's disease: New drugs, markets and companies D' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Therapeutic/Diagnostic Devices for Neurological Disorders
|
March 2007 |
£3265 |
50 % |
Stakeholder Opinions: Diagnostics in Neurology
Predictive Biomarkers Expand Drug Revenues
|
July 2008 |
£2005 |
46 % |
Alzheimer disease
new drugs, markets and companies
|
September 2008 |
£1885 |
45.5 % |
World Neurodegeneratives Disease Markets
|
February 2005 |
£1499 |
35 % |
CNS Market Trends, 2007 to 2010
Key Market Forecasts and Growth Opportunities
|
June 2007 |
£995 |
34.65 % |
Neurodegenerative Drug Futures
|
February 2005 |
£995 |
34.5 % |
Central Nervous System - Alzheimer Disease Drug Pipeline Report
|
February 2008 |
£1495 |
30 % |
CNS Drug Discoveries
What the Future Holds
|
November 2006 |
£1995 |
29.5 % |
Commercial Insight: CNS Market Overview
Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors
|
April 2008 |
£8000 |
29 % |
Neuroprotection
Drugs, Markets and Companies
|
September 2008 |
£1440 |
27 % |
MarketWatch: CNS
|
October 2008 |
£105 |
26.6 % |
Convergence of Biomarkers and Diagnostics, The
Therapy Area Analyses, Key Products and Future Trends
|
April 2008 |
£1995 |
26 % |
CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder (ADHD)
|
November 2006 |
£795 |
26 % |
Emerging Alzheimer's Disease Therapeutics
|
February 2004 |
£1775 |
25.9 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
23.5 % |
Innovations in CNS
Novel therapeutics and future R&D strategies
|
January 2007 |
£1495 |
22.4 % |
Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The
|
January 2007 |
£1515 |
22.05 % |
U.S. and Worldwide Monoclonal Antibody Medicine
Current Status and Future Trends
|
August 2008 |
£740 |
20.65 % |
Stakeholder Insight: Alzheimer's Disease
Prescribing trends indicate that neurologists are not adhering to guidelines
|
December 2006 |
£8000 |
20.3 % |
Eisai Prospects to 2110
Pipeline Products Performance Potential
|
October 2007 |
£595 |
19 % |
Eisai Pipeline - Products - Performance - Potential
|
June 2008 |
£595 |
19 % |
CNS Biomarkers: Players, products and prospects (Volume II)
|
August 2008 |
£595 |
18.55 % |
Transdermal Drug Delivery
Technologies, Markets, and Companies
|
September 2008 |
£1685 |
17.5 % |
The Future of Targeted Therapeutics
Key Technologies, New Therapy Area Applications and Leading Players
|
March 2008 |
£1995 |
17.15 % |
UK Pharmaceuticals & Healthcare
|
September 2006 |
£395 |
16.5 % |
Patient Empowerment
Empowered Patients Can Change Healthcare Outcomes And Impact The Pharmaceutical Industry
|
July 2007 |
£3000 |
16.45 % |
Over-the-Counter Diagnostic Products World Markets
|
September 2006 |
£2290 |
15.75 % |
Parkinson's Disease Market analysis and forecasts
2008-2012, 2017 & 2022
|
January 2008 |
£1499 |
15.05 % |
Market for Bioengineered Protein Drugs; The
|
January 2007 |
£3265 |
15.05 % |
Cannabinoids
A Potential Blockbuster
|
February 2005 |
£1499 |
14.7 % |
The Outlook For RNAi
Accelerating drug discovery and the development of RNAi therapeutics
|
January 2005 |
£1495 |
13.65 % |
Commercial Opportunities from Biomarkers
Transforming drug discovery, clinical development and molecular diagnostic
|
May 2006 |
£1495 |
13.65 % |
Drug Delivery in Central Nervous System Diseases
technologies,markets and companies
|
September 2008 |
£900 |
13.3 % |
CNS Generic Drugs: Prospects and Opportunities to 2012
|
April 2008 |
£995 |
12.6 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
September 2008 |
£1010 |
12.6 % |
Impact of Genomics on Clinical Trials and Medical Practice, The
|
April 2006 |
£1845 |
12.25 % |
Biomarkers
The Expanding Global Market
|
November 2007 |
£1625 |
11.55 % |
Angiogenesis Modulators
|
January 2008 |
£1885 |
11.2 % |
Rimonabant: The first of the Cannabinoid blockbusters
|
June 2007 |
£1499 |
11.2 % |
Apoptosis
|
January 2008 |
£1955 |
10.5 % |
RNAi
Technologies, Markets and Companies
|
September 2008 |
£2020 |
9.1 % |
Proteomics
Technologies, Markets and Companies
|
September 2008 |
£2355 |
9.1 % |
Neurogenomics and Neurotherapeutic Strategies
New Directions in Platforms, Targets, and Therapeutic Approaches
|
February 2005 |
£1950 |
9.1 % |
Personalized Medicine
scientific & commercial aspects
|
September 2008 |
£2695 |
8.75 % |
Biomarkers
|
January 2008 |
£2230 |
7.7 % |
Cell Therapy
Technologies, Markets and Companies
|
September 2008 |
£3030 |
7.35 % |
Molecular Diagnostics
Technologies, Markets and Companies
|
September 2008 |
£3030 |
6.65 % |
|
|
|
|
